logo
Misleading claims, outdated formulas: Most sunscreens fail to fully protect, report says

Misleading claims, outdated formulas: Most sunscreens fail to fully protect, report says

Yahoo21-05-2025

A new report is shining a light on the safety and effectiveness of sunscreen products sold in U.S. stores.
The Environmental Working Group published its 2025 Annual Guide to Sunscreens, finding that fewer than one in four SPF products met its criteria. The health research organization evaluated more than 2,200 products and found that fewer than 500 effectively protect a user's skin.
The report also shared insight into what it says are shortfalls within federal sunscreen regulations and the deceptive marketing practices by corporations.
"Many sunscreens still fall short by offering misleading claims about protection, using outdated formulas, some even containing ingredients with potential health concerns," the 2025 guide says. "Federal sunscreen rules have remained largely unchanged since 1999, leaving consumers to navigate products with uncertainty."
In 2019, the U.S. Food and Drug Administration proposed new aerosol-testing requirements for spray sunscreens to address concerns of inhalation risks and uneven application but never finalized them, according to the report.
Despite sprays representing 26% of all SPF products in 2025, the report warns the inhalation risk is still prevalent. There were multiple recalls regarding benzene contamination between 2021 to 2023.
The report also warned against products with an undisclosed "fragrance," revealing that 36% of said products this year included allergens, hormone disruptors and carcinogens.
In 2022, a federal law required the FDA to develop guidelines for disclosing fragrance allergens in certain SPF products by July 2024, the report stated. Yet no proposal has been shared as of May, with the Environmental Working Group warning that recent staffing shortages enforced by the Trump Administration may further slow the process.
The FDA did not immediately respond to USA TODAY's request for comment late Tuesday.
"In the meantime, (the Environmental Working Group) continues to urge consumers to choose fragrance-free sunscreens or those carrying the EWG Verified® mark, which guarantees ingredient transparency and the absence of harmful fragrance chemicals," the guide reads.
The report also noted a decline in sunscreen products that contain oxybenzone and Vitamin A, amid growing awareness surrounding the safety and effectiveness of both.
The high-skin absorption of oxybenzone in non-mineral sunscreens poses several health concerns like hormones disruption and is harmful for aquatic and marine ecosystems, the report stated. In 2016, oxybenzone was used in 70% of non-mineral sunscreens. Now that number is at 9%.
Research shows that Vitamin A in SPF products can degrade in sunlight, possibly worsening skin damage more than not wearing sunscreen, according to the working group. Only 2% of SPF products currently contain Vitamin A, typically in the form of retinyl palmitate, a significant decline compared to 41% in 2010.
The 2025 Annual Guide to Sunscreens report offered the following advice for sunscreen users hoping to stay safe from harmful sun rays and avoid the risk of skin cancer.
Don't fall for high SPF labels
Remember to reapply often
Choose lotions and sticks over sprays
Avoid ingredients of concern and look for mineral products with zinc oxide
Use EWG's list of top-rated sunscreens and the EWG Verified mark to find the products that work best for you
Wear clothing, hats, and sunglasses for additional sun protection
Avoid the sun during peak hours (typically 10 a.m. to 4 p.m.)
Protect kids, whose skin is especially sensitive to UV damage
Be cautious around water and sand, which reflect UV rays and increase exposure
Check the UV index in your area for real-time guidance on sun safety
To see the entire 2025 Annual Guide to Sunscreens report, click here.
This article originally appeared on USA TODAY: Fewer than 1 in 4 sunscreen products are fully safe, effective: Report

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website

Yahoo

timean hour ago

  • Yahoo

JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website

- A refreshed global brand signals JCR's expanded international presence and unwavering focus on rare and genetic diseases worldwide - HYOGO, Japan, June 06, 2025--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. "At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world," said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. "In September, we celebrate the 50th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases." The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website: View source version on Contacts Investors & Media:JCR Pharmaceuticals Co., Communicationsir-info@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website

Business Wire

timean hour ago

  • Business Wire

JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website

HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. 'At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'In September, we celebrate the 50 th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.' The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo ® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo ® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website:

Rep. Don Scott to discuss threats to Medicaid in Norfolk
Rep. Don Scott to discuss threats to Medicaid in Norfolk

Yahoo

timean hour ago

  • Yahoo

Rep. Don Scott to discuss threats to Medicaid in Norfolk

NORFOLK, Va. (WAVY) — Virginia House Speaker Don Scott will join other advocates for reproductive freedom in Norfolk on Friday to speak about the threat to Medicaid. The stop at the Slover Library is the final stop of a statewide tour called 'Protect our Medicaid.' The goal of the tour, according to a release, is to raise awareness of the threat cuts to Medicaid could have on Virginia families. Those with the Protect our Medicaid group said the federal cuts to Medicaid under the Trump Administration's 'Big, Beautiful Bill' could cause over 250,000 Virginians to lose their healthcare, with nearly 47,000 veterans alone in the state covered by Medicaid. The bill includes a proposed $625 million cut in Medicaid — which could cause 7.6 million people nationwide to lose health coverage in less than a decade, according to budget analysis. A release from the group states that Medicaid is the largest source of funding for home care in the United States, with home care for older adults and people with disabilities rising across the country. GOP bill raises fears of major reduction in home care for seniors, disabled The discussion will address how cuts to both Medicaid and Planned Parenthood can impact the Hampton Roads regional economy and how it will harm Virginia families. The Protect our Medicaid tour is expected to be held in the third floor at the Slover Library starting at 11 a.m. Continue to check for updates. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store